Incyte Reports Strong Q4 Revenue Growth of 28% Driven by Jakafi and Opzelura Performance
Key Insights
Incyte achieved a 28% year-over-year increase in fourth-quarter revenue to $1.51 billion, with full-year 2025 revenue reaching $5.14 billion, marking a 21% annual gain.
Jakafi generated $3.1 billion in product revenue with 11% annual growth, while Opzelura demonstrated explosive 33% growth to $678 million in 2025.
The company increased R&D spending by 31% to $611.4 million in Q4 2025 to advance 14 registration-enabling studies across seven compounds ahead of Jakafi patent expirations beginning in 2028.
Incyte Corporation concluded its 2025 fiscal year with robust financial performance, reporting a significant 28% year-over-year increase in fourth-quarter revenue to $1.51 billion. For the full year 2025, total revenue climbed to $5.14 billion, marking a 21% gain and surpassing the company's own product revenue forecasts.
The biotechnology firm's revenue strength stems from two primary growth engines. Jakafi, the company's flagship product, remains the cornerstone of its portfolio, generating $3.1 billion in product revenue with an 11% annual increase and accounting for approximately 60% of total annual revenue. Simultaneously, the topical cream Opzelura demonstrated explosive growth, with revenue soaring 33% to $678 million in 2025, solidifying its role as a major secondary growth driver.
Pipeline Development Intensifies Ahead of Patent Cliff
A critical challenge looms on the horizon as key patents for the original Jakafi formulation are set to begin expiring in 2028. To navigate this "patent cliff," Incyte has implemented an aggressive pipeline development strategy, ramping up research and development spending by 31% in Q4 2025 to $611.4 million.
The company's development plan is ambitious, with 14 registration-enabling studies across seven distinct compounds expected to be active by the end of 2026. A major near-term milestone is the anticipated mid-2026 approval and launch of Jakafi XR, an extended-release version designed to extend the product's lifecycle.
Key Regulatory Milestones on the Horizon
Incyte anticipates seven clinical data readouts in 2026 that will shape its future market position. Following positive Phase 3 frontMIND trial results for tafasitamab plus lenalidomide and R-CHOP in first-line diffuse large B-cell lymphoma (search), a supplemental Biologics License Application (sBLA) for tafasitamab is slated for submission in the first half of 2026, with plans for an expanded filing in 2026.
Additionally, Incyte expects the U.S. Food and Drug Administration (FDA) to accept the New Drug Application for povorcitinib in the first quarter of 2026. These regulatory events are crucial for reducing long-term dependence on Jakafi and establishing new revenue streams.
Portfolio Diversification Strategy
Further diversification is underway with contributions from newer market entrants like Niktimvo and Zynyz, broadening the company's therapeutic portfolio. Management has provided product revenue guidance for 2026 in a range of $4.77 billion to $4.94 billion, reflecting confidence in the company's growth trajectory despite upcoming patent challenges.
The coming years will test whether Incyte's substantial investment in its clinical pipeline can successfully generate new revenue streams to compensate for the impending loss of exclusivity for its most significant product. The company's recent momentum, including positive Phase 3 results and strong financial performance, positions it strategically as it navigates this critical transition period.